Table 2.

Translational status, academic momentum, and bedside barriers in sepsis research.

Research domain & focus	Current evidence status & academic momentum	Clinical translation barriers & implications	Strategic future recommendations (policy & research)
Translational Impact & Evidence Evolution	• Robust paradigm shift from Level 5 expert consensus (e.g., SIRS/Sepsis-1/2) toward Level 1/2 clinical validation (Sepsis-3 criteria and protocolized care bundles).	• Operationalization Heterogeneity: Sepsis-3 standardized early diagnosis, but real-time bedside implementation of the SOFA score relies heavily on institutional resource availability and rapid clinical tracking.	• Policy: Dynamically update (SSC guidelines to incorporate organ-specific clinical endotypes. • Research: Prioritize Phase III clinical trials shifting focus from broad immunomodulation to precision targeted interventions.
Digital Intensive Care & Predictive Analytics	• Intense algorithmic momentum driven by active citation bursts: machine learning (strength: 149.72), artificial intelligence (strength: 50.77), and prediction models (strength: 49.49).	• Infrastructural Barriers & Opacity: Deploying AI models for real-time risk stratification (e.g., SA-AKI or 28-day mortality) demands massive electronic medical record infrastructure and risks clinical distrust due to “black-box” algorithms.	• Policy: Mandate rigorous safety, equity, and cost-effectiveness audits before hospital-wide AI deployment. • Research: Fund multi-institutional external validation of predictive algorithms to ensure cross-population reliability.
Global Health Equity & Geographic Disparities	• Pronounced publication asymmetry: United States dominance (30.32% output) contrast with a severe citation impact gap (China: 21.86 vs. Netherlands: 77.58 citations/publication); extreme scarcity of structured data from LMICs.	• Epidemiological Mismatch: The global sepsis mortality burden resides predominantly in resource-limited settings, yet available literature and international guidelines remain heavily biased toward high-income Western healthcare paradigms.	• Policy: Prioritize international funding for affordable point-of-care testing (POCT) and secure antibiotic supply chains in LMICs. • Training: Subsidize open-access publishing models for LMIC researchers and launch bidirectional global health fellowships.
Microenvironmental Heterogeneity & Pathophysiological Drivers	• Rapidly accelerating citation bursts highlighting mechanistic frontiers: Mendelian randomization (strength: 52.96), gut microbiota (strength: 48.13), and NLRP3 inflammasome (strength: 24.72).	• Mechanistic Translational Gap: The clinical focus is evolving from macroscopic fluid/vasopressor titration to micro-ecological and cellular regulation (e.g., the gut-lung axis), but high-fidelity human translational evidence remains limited.	• Research: Prioritize translational clinical trials targeting novel non-apoptotic RCD pathways (e.g., pyroptosis, ferroptosis) and expand causal inference via Mendelian randomization for robust drug repurposing.
Subpopulation Divergence & Antimicrobial Stewardship	• High-density thematic clustering and emergence of neonatal sepsis, maternal sepsis, and antimicrobial resistance (strength: 33.14) as highly relevant independent nodes.	• Guideline Extrapolation Risks: Standardized adult sepsis protocols fail to account for the unique microbiological spectrum, altered pharmacokinetics, and distinct physiological profiles of maternal and pediatric cohorts.	• Policy: Strictly enforce global, multi-tier antimicrobial stewardship policies to combat escalating resistance. • Research: Accelerate the development and validation of subpopulation-specific therapeutic bundles tailored exclusively to neonatal and pregnancy-associated sepsis.

AI, artificial intelligence; LMICs, low- and middle-income countries; NLRP3, NLR family pyrin domain containing 3; POCT, point-of-care testing; RCD, regulated cell death; SA-AKI, sepsis-associated acute kidney injury; SOFA, sequential organ failure assessment; SSC, surviving sepsis campaign.